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Is nitrogen mustard contamination responsible for the reported MT-45 
toxicity?  
 
Jason Wallach, Hamilton Morris and Simon D. Brandt  
 
Helander et al. are commended for disseminating their case reports in the recent 
publication entitled “Acute skin and hair symptoms followed by severe, delayed eye 
complications in subjects using the synthetic opioid MT-45”.1 We have followed 
reports of side effects associated with MT-45 use for several years and the above 
publication serves as an important reminder of the risks of harm involved in the 
unregulated use of new psychoactive substances.  
As pointed out in the report the symptoms described in these case reports are 
reminiscent of chemotherapeutic agents.1 The authors reported that anticancer 
drugs could not be detected, thus, excluding their involvement in the reported 
clinical features.1 We wish to point out that a number of published synthetic routes 
to MT-45 describe the use of N,N-bis(2-chloroethyl)cyclohexylamine (1) as an 
alkylating agent in the final step of the synthesis.2-5 An alternate route using N,N-
bis(2-chloroethyl)-1,2-diphenylethylamine (2) (Fig. 1) as the alkylating 
intermediate has also been reported.2-4 These reagents are nitrogen mustards and 
it’s conceivable that other synthetic routes might employ different mustard 
intermediates at various stages as well. Such agents would likely be missed in 
analysis as they are not employed as anticancer drugs or commonly encountered. 
Metabolic transformation of nitrogen mustard contaminants could further 
complicate their detection in a clinical setting.  
Nitrogen mustards are reactive alkylating agents with recognized uses in 
chemotherapy5 but also chemical warfare6, and they are known to cause many of the 
same adverse effects associated with use of MT-45.5 The reagents employed in MT-
45 synthesis (1, 2) and/or partially reacted side products (for example structures 3-
4 in Figure 1) might also act as an alkylating agent due to their electrophilic nature 
and this raises the question as to whether the symptoms described by Helander et 
al. 1 as well as those described on drug discussion forums could reflect the presence 
of ill-purified batches of MT-45. Poisoning with nitrogen mustards could have long 
lasting consequences for the user, including carcinogenesis. 
It should not be excluded that MT-45 was the sole agent responsible for the 
reported symptoms and the authors propose several potential leads. However the 
search for contaminants associated with MT-45 synthesis might also be worthy of 
investigation. Conclusive evidence will require detection of contaminated MT-45 
samples along with follow-up studies in animal models. Our own analysis of a single 
sample of MT-45 from an online vendor obtained in January 2015 did not appear to 
contain any major organic impurities but as different distributors likely obtain this 
substance from distinct sources or manufacturers, it seems possible only some 
batches would be contaminated. The analysis of blood samples for the presence of 
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the alkylating agents and some potential bio-marker metabolites comparable to 
those seen with related nitrogen mustards8 might also be worthy of investigation. 
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Figure 1. Mustard intermediates used in the synthesis of MT-45 and possible 
alkylating agent side products.  
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